Oak Thistle LLC Takes $1.50 Million Position in Hologic, Inc. $HOLX

Oak Thistle LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 22,185 shares of the medical equipment provider’s stock, valued at approximately $1,497,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC bought a new stake in Hologic in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the 2nd quarter worth about $33,000. Cromwell Holdings LLC lifted its position in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares during the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new position in Hologic during the 2nd quarter valued at about $40,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Down 0.1%

HOLX opened at $74.93 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.06 and a current ratio of 3.75. The company has a market capitalization of $16.70 billion, a PE ratio of 30.21, a P/E/G ratio of 2.13 and a beta of 0.70. The stock’s fifty day moving average is $73.45 and its 200-day moving average is $68.59. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.34.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the company earned $1.01 earnings per share. Hologic’s revenue was up 6.2% compared to the same quarter last year. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on HOLX. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and raised their price target for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, Argus increased their target price on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Five equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.29.

Insider Activity at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.